Second-line therapy of advanced ovarian cancer with GnRH analogs

International Journal of Gynecological Cancer

Volumn 14, Issue 5, 2004, Pages 799-803

  Balbi, Giancarlo ^a,b   Piano, L D ^a   Cardone, A ^a   Cirelli, G ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NONE   (Italy)

Author keywords

Advanced ovarian cancer; Analogs; Second line therapy

Indexed keywords

CARBOPLATIN; GONADORELIN DERIVATIVE; LEUPRORELIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; FEMALE; HUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUPROLIDE; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 4544264455     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2004.014511.x     Document Type: Article

References (26)

1. Conte PF, Cianci C, Gadducci A. Up date in the management of advanced ovarian carcinoma. Crit Rev Hematol 1999;32:49-58.
2. Williams LL. Secondary cytoreduction of ovarian malignancies. In: Markman M, Oskens WJ, eds. Cancer of the Ovary. New York: Raven Press, 1993, 187-203.
3. Balbi GC, Colacurci N, Di Grazia F. L'uso degli agonisti dell'LHRH nel trattamento del carcinoma ovarico in fase avanzata 1994. L'ovaio: fisiopatologia benigna e maligna. Ed.CIC.
4. Stadel BV. The etiology and prevention of ovarian cancer. Am J Obstet Gynecol 1975;123:772-4.
5. Emons G, Pahwa GS, Brack C, Sturm R, Oberheuser F, Knuppen R. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 1989;25:215-21.
6. Kang SK, Cheng KW, Nathwani PS, Choi KC, Leung PC. Autocrine role of gonadotropin-releasing hormone and its receptor in ovarian cancer cell growth. Endocrine 2000;13:297-304.
7. Kim JH, Park DC, Kim JW et al. Antitumor effect of GnRH agonist in epithelial ovarian cancer. Gynecol Oncol 1999;74:170-80.
8. Volker P, Grundker C, Schmidt O, Schulz KD, Emons G. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 2002;186:171.
9. Gunthert AR, Grundker C, Hollmann K, Emons G. Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells. Biochem Biophys Res Commun 2002;294:11-5.
10. Grundker C, Volker P, Schulz KD, Emons G. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. Gynecol Oncol 2000;78:194-202.
11. Peterson CM, Jolles CJ, Carrel DT et al. GnRH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) heterotransplanted in the nude mouse is characterized by latency and transience. Gynecol Oncol 1994;52:26-30.
12. Adelson MD, Reece MT. Effects of gonadotropin-releasing hormone analogues on ovarian epithelial tumours. Clin Obstet Gynecol 1993;36:690-700.
13. Parmar H, Philips RH, Rustin G, Lightam SL, Shally AV. Therapy of advanced ovarian cancer with d-Trp-6-LHRH (decapeptyl) microcapsules. Biomed Pharmacother 1988;42:531-8.
14. Kanavagh JJ, Roberts W, Townsend P, Hewitt S. Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol 1989;7:115-8.
15. Bruckner HW, Montana BT. Treatment of advanced refractory ovarian carcinoma with a gonadotropin releasing hormone analogue. Am J Obstetrics Gynecol 1989;161:1216-8.
16. Thigpen JT, Blessing JA, Ball H et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemiotherapy: a Gynecologic Oncology Group Study. J Clin Oncol 1994;12:1748-53.
17. Eons G, Ortmann O, Teichert HM et al. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemiotherapy in patients with advanced ovarian carcinoma. Cancer 1996;78:1452-60.
18. Erickson LD, Hartmann LC, Su JQ et al. Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma. Gynecol Oncol 1994;54:196-200.
19. Falkson CI, Falkson HC, Falkson G. Cisplatin versus cisplatin plus d-Trp-6LHRH in the treatment of ovarian cancer: a pilot trial to investigate the effect of the addition of GnRH analogue to cisplatin. Oncology 1996;53:313-7.
20. Paskeviciute L, Roed H, Engelholm S. No. rules without exception: long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer. Gynecol Oncol 2002;86:297-301.
21. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B. Tamoxifen in platinum refractory ovarian cancer. A Gynecologic Oncology Group ancillary report. Gynecol Oncol 1996;62:4-6.
22. Van der Vange N, Greggi S, Burger W, Kenemans P, Vermerken JB. Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol 1995;34:813-20.
23. Scambia G, Benedetti Panici P, Greggi S, Baiocchi G, Perrone L, Mancuso S. Phase II study with an LHRH analog in advanced ovarian cancer. J Gynecol Endocrinol 1990;VI:5-7.
24. Jager W, Sauerbrei W, Beck E et al. A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer. Anticancer Res 1995;15:2639-42.
25. Zidan J, Zohar S, Mijiritzky I, Kral S, Bilenca B. Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy. Isr Med Assoc J 2002;4:597-9.
26. Marinaccio M, D'Addario VD, Serrati A, Pinto V, Gagnazzo G. Leuprolide acetate as a salvage therapy in relapsed epithelial ovarian cancer. Eur J Clin Oncol 1996;17:286-8.